Atara Biotherapeutics
ATRA
ATRA
121 hedge funds and large institutions have $1.68B invested in Atara Biotherapeutics in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0.14% more ownership
Funds ownership: 4.09% → 4.23% (+0.14%)
13% less capital invested
Capital invested by funds: $1.92B → $1.68B (-$240M)
Holders
121
Holding in Top 10
4
Calls
$4.58M
Puts
$1.5M
Top Buyers
| 1 | +$19.2M | |
| 2 | +$11.7M | |
| 3 | +$11.4M | |
| 4 |
HCM
Highline Capital Management
New York
|
+$10.1M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$9.73M |
Top Sellers
| 1 | -$17.2M | |
| 2 | -$14.6M | |
| 3 | -$8.77M | |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$4.13M |
| 5 |
Goldman Sachs
New York
|
-$3.01M |